Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome.
about
18F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases.Thermal Ablation in the Management of Colorectal Cancer Patients with Oligometastatic Liver Disease.Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection.Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status.Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases.Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes.Immediate Post-ablation FDG-injection and corresponding Standardized Uptake Value is a Surrogate Biomarker of Local Tumor Progression after Thermal Ablation of Colorectal Carcinoma Liver Metastases.Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control.Microwave ablation of liver malignancies: comparison of effects and early outcomes of percutaneous and intraoperative approaches with different liver conditions : New advances in interventional oncology: state of the art.A Comparative Study of Ablation Boundary Sharpness After Percutaneous Radiofrequency, Cryo-, Microwave, and Irreversible Electroporation Ablation in Normal Swine Liver and Kidneys.Evaluation of microwave ablation of liver malignancy with enabled constant spatial energy control to achieve a predictable spherical ablation zone.Treatment effect of conversion therapy and its correlation with VEGF expression in unresectable rectal cancer with liver metastasis.Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration
P2860
Q33695043-D97BF094-A97B-4631-AAC0-66D6D3B0E1ABQ38726773-C305E8DC-0C1C-44D0-AD0F-676429E9A8E6Q38791333-CFAE4C33-4B75-4210-96FF-AFEEE6AB6C21Q40317208-FDD31579-458A-40EA-8CE4-9DFB9A7245B3Q42371613-15108094-58E2-48D3-991A-E7396F18B255Q47093792-4EC0F9EB-E2AB-4172-9DA6-964C6461940BQ50036604-C5236137-65F7-4206-9E1C-3AD743C84919Q50083772-C88036ED-3E4C-42EF-9E51-E4160478B1C9Q50881709-ADBCE150-7E7C-432E-986E-D7EE49578E7BQ52770098-1C2E134A-1220-4957-8C5C-F6D9B773124FQ53723381-25D00CBC-9B75-4534-844D-F37DCE46F2E5Q55359283-1091E007-749F-4158-8FB0-6928F47232D1Q58565410-8F8DEEFB-90D5-445F-B66E-54CD60A684C2
P2860
Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Colorectal Cancer Liver Metast ...... to Predict Oncologic Outcome.
@en
type
label
Colorectal Cancer Liver Metast ...... to Predict Oncologic Outcome.
@en
prefLabel
Colorectal Cancer Liver Metast ...... to Predict Oncologic Outcome.
@en
P2093
P2860
P1433
P1476
Colorectal Cancer Liver Metast ...... to Predict Oncologic Outcome.
@en
P2093
Afsar Barlas
Alessandra R Garcia
Anne M Covey
Constantinos T Sofocleous
David S Klimstra
Elena N Petre
Joseph P Erinjeri
Karen T Brown
Katia O Manova-Todorova
Lydia M Petrovic
P2860
P304
P356
10.1148/RADIOL.2016151005
P407
P50
P577
2016-03-24T00:00:00Z